Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

22 Feb 2019

Abstract excerpt

BACKGROUND: Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in cinical trials for bladder cancer patients that carry alterations in homologous DNA repair genes, letting to envisage susceptibility to the Poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors. MAIN BODY: PARP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30791940
DOI: 10.1186/s13046-019-1089-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatmentPMID 30791940Read ↗

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity Read ↗

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignanciesSemantic proximity Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancerSemantic proximity Read ↗

PARP Inhibitors in Prostate and Urothelial CancersSemantic proximity Read ↗

DNA-Damage-Repair Gene Alterations in Genitourinary MalignanciesSemantic proximity Read ↗

Latest progress in molecular biology and treatment in genitourinary tumours.Semantic proximity Read ↗

The emerging role of PARP inhibitors in prostate cancer.Semantic proximity Read ↗

Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.Semantic proximity Read ↗

Development of PARP and Immune-Checkpoint Inhibitor CombinationsSemantic proximity Read ↗

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancerSemantic proximity Read ↗

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune CheckpointsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.